Celldex Therapeutics Inc. is discontinuing its lead program, the antibody-drug conjugate glembatumumab vedotin (glemba), after it failed to help women with tough-to-treat metastatic triple-negative breast cancers (TNBC) stay both alive and progression-free for longer than Roche Holding AG’s Xeloda (capecitabine), missing the primary endpoint of a phase IIb study. The hard blow, which will also bring an end to a phase II combination study in melanoma, precipitated plans for restructuring and re-evaluation at the company as its shares (NASDAQ:CLDX) tumbled 64.6 percent to close at 76 cents on Monday.